Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp. develops enabling technologies and services for pharmaceutical, high-value chemical, and related laboratory markets. Company news commonly covers Self-Driving Laboratories, the DirectInject-LC™ automated sampling and analysis product, contract research services, customer installations, technology collaborations, and technical outreach to scientific and investor audiences.
Updates also address financial results, product fulfillment, hiring and operating expenses tied to growth, and Telescope's lithium processing portfolio, including DualPure™ and ReCRFT™ technologies for battery-material applications. The company's announcements connect automation, chemical process development, and materials R&D with recurring disclosures on revenue drivers, partnerships, and commercialization activity.
Telescope Innovations (OTCQB: TELIF) announced that Ali Pejman has resigned from its Board of Directors, effective July 14, 2026. According to Telescope, Pejman is expected to continue supporting the company as a consultant under an agreement to be finalized shortly, while the Board actively searches for a qualified replacement in line with Canadian securities laws and CSE policies.
Telescope Innovations (OTCQB: TELIF) will attend the Fastmarkets Global Lithium, Battery & Critical Materials conference in Las Vegas from June 23-25, 2026.
The company aims to advance commercial discussions for its Self-Driving Labs, automated sampling systems including DirectInject-LC™, and licensing of its high-purity lithium sulfide production process.
Telescope Innovations (OTCQB:TELIF) reported Q3 FY2026 results for the quarter ended May 31, 2026. Revenue was CAD 2.12 million with an adjusted EBITA loss of CAD 1.06 million. Expenses reached CAD 3.53 million.
Year-to-date gross revenue rose to CAD 6.5 million from CAD 3.6 million, an 80% increase. Operationally, Telescope secured a third Self-Driving Lab contract with a major global pharmaceutical company, advanced a collaboration with AGI Group on reactor technology, and invoiced an analysis platform based on its DirectInject-IC™ technology for lithium battery materials.
Telescope Innovations (OTCQB: TELIF) will present at Planet MicroCap Las Vegas 2026 on June 17, 2026, at 4:30 pm PST. Dr. Jeffrey Sherman will discuss DirectInject-LC reaction sampling, the AGI SDA reactor collaboration, and recent Self-Driving Lab deployments in Korea, Europe, and at Pfizer.
Telescope Innovations (OTCQB: TELIF) announced that Founder and CTO Professor Jason Hein received the 2026 SCI Canada LeSueur Memorial Award. The honour recognizes his technical excellence and contributions to Canadian industry in chemical creativity and innovation.
The award highlights Hein’s work linking chemistry, automation, AI, and Self-Driving Lab technology.
Telescope Innovations (OTCQB: TELIF) signed an agreement to deploy a Self-Driving Lab (SDL) platform for a major global pharmaceutical company at its European operations. This will be Telescope's third SDL deployment in its 2026 fiscal year.
Earlier in the fiscal year, SDL platforms were installed at the Korean Pharmaceutical and Biopharma Manufacturers Association and at Pfizer. According to Telescope, adding a third top-tier pharma partner highlights growing international demand for its autonomous lab technology.
Telescope Innovations (OTCQB: TELIF) outlined its spring 2026 conference and events lineup, targeting pharmaceutical, academic, and investor audiences.
The company is presenting and exhibiting its Self-Driving Labs and DirectInject-LC technologies, while CTO Dr. Jason Hein delivers multiple keynotes and accepts the LaSueur Memorial Award, alongside dedicated investor engagement events.
Telescope Innovations (OTCQB: TELIF) reported Q2 FY2026 results for the quarter ended February 28, 2026, with revenues of $1.64M (up from $1.00M in Q2 FY2025) and a year-to-date gross revenue of $4.3M versus $2.2M a year earlier. Adjusted EBITA loss was $0.71M, in line with management expectations.
Revenue growth was driven by delivery of Self-Driving Laboratories, including a second SDL delivered to Pfizer. Expenses rose to $3.11M to support hiring, product fulfillment and sales activity. Telescope also expanded lab space for lithium processing and reported battery-grade lithium from its ReCRFT process.
Telescope Innovations (OTCQB: TELIF) announced that Dr. Joel M. Hawkins has expanded his consulting role to support the company’s work in automated chemistry sampling and Self-Driving Laboratories (SDLs). Dr. Hawkins brings experience automating complex chemistry workflows and prior collaborations with Pfizer and Technobis.
He will support development of the DirectInject-LC platform, contribute to a Telescope–AGI reactor collaboration, and help scale SDL deployments integrating robotics, inline analytics, and AI.
Telescope Innovations (OTCQB: TELIF) signed a Development and Collaboration Agreement with AGI Group's Synthesis, Digitization, and Automation program (AGI SDA) on March 16, 2026 to co-develop an AI-ready chemical reactor and sampling platform.
The partners aim to integrate Telescope's DirectInject-LC sampling technology with AGI's reactor and SYNTO platform, with a broader effort involving six major biopharma companies and a planned SYNTO release mid 2027.